Copyright Reports & Markets. All rights reserved.

Global Disitamab Vedotin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Disitamab Vedotin Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Monoclonal Antibody, mAb
    • 1.3.3 Polyclonal Antibody, pAb
    • 1.3.4 Bispecific Antibody, bsAb
  • 1.4 Market Analysis by Strength
    • 1.4.1 Overview: Global Disitamab Vedotin Consumption Value by Strength: 2021 Versus 2025 Versus 2032
    • 1.4.2 60 mg/vial
    • 1.4.3 120 mg/vial
  • 1.5 Market Analysis by Production Technology
    • 1.5.1 Overview: Global Disitamab Vedotin Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Originator
    • 1.5.3 Generic
  • 1.6 Market Analysis by Dosage Form
    • 1.6.1 Overview: Global Disitamab Vedotin Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.6.2 Lyophilized Powder for Injection
    • 1.6.3 Injection Solution
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Disitamab Vedotin Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Gastric Cancer
    • 1.7.3 Urothelial Carcinoma (UC)
    • 1.7.4 Breast Cancer
    • 1.7.5 Others
  • 1.8 Global Disitamab Vedotin Market Size & Forecast
    • 1.8.1 Global Disitamab Vedotin Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Disitamab Vedotin Sales Quantity (2021-2032)
    • 1.8.3 Global Disitamab Vedotin Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 RemeGen
    • 2.1.1 RemeGen Details
    • 2.1.2 RemeGen Major Business
    • 2.1.3 RemeGen Disitamab Vedotin Product and Services
    • 2.1.4 RemeGen Disitamab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 RemeGen Recent Developments/Updates
  • 2.2 Seagen
    • 2.2.1 Seagen Details
    • 2.2.2 Seagen Major Business
    • 2.2.3 Seagen Disitamab Vedotin Product and Services
    • 2.2.4 Seagen Disitamab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Seagen Recent Developments/Updates
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Disitamab Vedotin Product and Services
    • 2.3.4 Pfizer Disitamab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer Recent Developments/Updates

3 Competitive Environment: Disitamab Vedotin by Manufacturer

  • 3.1 Global Disitamab Vedotin Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Disitamab Vedotin Revenue by Manufacturer (2021-2026)
  • 3.3 Global Disitamab Vedotin Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Disitamab Vedotin by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Disitamab Vedotin Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Disitamab Vedotin Manufacturer Market Share in 2025
  • 3.5 Disitamab Vedotin Market: Overall Company Footprint Analysis
    • 3.5.1 Disitamab Vedotin Market: Region Footprint
    • 3.5.2 Disitamab Vedotin Market: Company Product Type Footprint
    • 3.5.3 Disitamab Vedotin Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Disitamab Vedotin Market Size by Region
    • 4.1.1 Global Disitamab Vedotin Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Disitamab Vedotin Consumption Value by Region (2021-2032)
    • 4.1.3 Global Disitamab Vedotin Average Price by Region (2021-2032)
  • 4.2 North America Disitamab Vedotin Consumption Value (2021-2032)
  • 4.3 Europe Disitamab Vedotin Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Disitamab Vedotin Consumption Value (2021-2032)
  • 4.5 South America Disitamab Vedotin Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Disitamab Vedotin Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 5.2 Global Disitamab Vedotin Consumption Value by Type (2021-2032)
  • 5.3 Global Disitamab Vedotin Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 6.2 Global Disitamab Vedotin Consumption Value by Application (2021-2032)
  • 6.3 Global Disitamab Vedotin Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 7.2 North America Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 7.3 North America Disitamab Vedotin Market Size by Country
    • 7.3.1 North America Disitamab Vedotin Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Disitamab Vedotin Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 8.2 Europe Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 8.3 Europe Disitamab Vedotin Market Size by Country
    • 8.3.1 Europe Disitamab Vedotin Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Disitamab Vedotin Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Disitamab Vedotin Market Size by Region
    • 9.3.1 Asia-Pacific Disitamab Vedotin Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Disitamab Vedotin Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 10.2 South America Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 10.3 South America Disitamab Vedotin Market Size by Country
    • 10.3.1 South America Disitamab Vedotin Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Disitamab Vedotin Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Disitamab Vedotin Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Disitamab Vedotin Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Disitamab Vedotin Market Size by Country
    • 11.3.1 Middle East & Africa Disitamab Vedotin Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Disitamab Vedotin Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Disitamab Vedotin Market Drivers
  • 12.2 Disitamab Vedotin Market Restraints
  • 12.3 Disitamab Vedotin Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Disitamab Vedotin and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Disitamab Vedotin
  • 13.3 Disitamab Vedotin Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Disitamab Vedotin Typical Distributors
  • 14.3 Disitamab Vedotin Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Disitamab Vedotin market size was valued at US$ 329 million in 2025 and is forecast to a readjusted size of US$ 1181 million by 2032 with a CAGR of 16.9% during review period.
    Disitamab Vedotin is an antibody–drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It consists of a humanized anti-HER2 monoclonal antibody, a cleavable linker, and a cytotoxic microtubule inhibitor payload. The antibody component specifically recognizes HER2-expressing tumor cells and delivers the cytotoxic agent into the cells, where the active component is released to inhibit microtubule polymerization and induce tumor cell apoptosis. This drug is mainly used for the treatment of various HER2-expressing solid tumors, such as gastric cancer and urothelial carcinoma. It is characterized by strong targeting specificity, significant efficacy, and manageable toxicity, making it an important innovative therapy in the field of HER2-targeted treatmentsIn 2025, global production of disitamab vedotin (RC48, trade name: Aidixi®) reached approximately 320,000 units.
    Disitamab Vedotin, as a HER2-targeting antibody–drug conjugate (ADC), is currently in a rapid growth phase within the precision oncology market. With the expanding patient population of HER2-expressing tumors such as gastric cancer and urothelial carcinoma, along with increasing HER2 testing rates, the target population for this drug continues to grow, driving sustained market demand. Meanwhile, the maturation of ADC technology platforms and the accumulation of clinical data have led to increasing recognition of its efficacy and safety, enhancing its market competitiveness. However, competition is also intensifying, including from global blockbuster ADC products such as Enhertu as well as other HER2-targeted therapies, which pose direct competitive pressure. Overall, the market for Disitamab Vedotin represents a “high-value, high-growth” segment, with future expansion mainly driven by indication expansion, development in HER2-low populations, and global commercialization efforts.
    This report is a detailed and comprehensive analysis for global Disitamab Vedotin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Disitamab Vedotin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Disitamab Vedotin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Disitamab Vedotin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Disitamab Vedotin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Disitamab Vedotin
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Disitamab Vedotin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include RemeGen, Seagen, Pfizer, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Disitamab Vedotin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal Antibody, mAb
    Polyclonal Antibody, pAb
    Bispecific Antibody, bsAb
    Market segment by Strength
    60 mg/vial
    120 mg/vial
    Market segment by Production Technology
    Originator
    Generic
    Market segment by Dosage Form
    Lyophilized Powder for Injection
    Injection Solution
    Market segment by Application
    Gastric Cancer
    Urothelial Carcinoma (UC)
    Breast Cancer
    Others
    Major players covered
    RemeGen
    Seagen
    Pfizer
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Disitamab Vedotin product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Disitamab Vedotin, with price, sales quantity, revenue, and global market share of Disitamab Vedotin from 2021 to 2026.
    Chapter 3, the Disitamab Vedotin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Disitamab Vedotin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Disitamab Vedotin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Disitamab Vedotin.
    Chapter 14 and 15, to describe Disitamab Vedotin sales channel, distributors, customers, research findings and conclusion.

    Buy now